Combination of | |
---|---|
Sacubitril | Neprilysin inhibitor |
Valsartan | Angiotensin II receptor antagonist |
Clinical data | |
Trade names | Entresto, Azmarda, Neparvis, others |
Other names | LCZ696 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a615039 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
PubChem CID | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C96H120N12Na6O21 |
Molar mass | 1916.018 g·mol−1 |
3D model (JSmol) | |
| |
|
Sacubitril/valsartan, sold under the brand name Entresto among others, is a fixed-dose combination medication for use in heart failure. It consists of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker valsartan. The combination is sometimes described as an "angiotensin receptor-neprilysin inhibitor" (ARNi).[9] In 2016, the American College of Cardiology/American Heart Association Task Force recommended it as a replacement for an ACE inhibitor or an angiotensin receptor blocker in people with heart failure with reduced ejection fraction.[10]
Potential side effects include angioedema, nephrotoxicity, and low blood pressure.[10]
It was approved for medical use in the United States and in the European Union in 2015,[11][12][13][7] and in Australia in 2016.[1] In 2021, it was the 189th most commonly prescribed medication in the United States, with more than 2 million prescriptions.[14][15] It is available as a generic medication.[16]
Entresto FDA label
was invoked but never defined (see the help page).{{cite journal}}
: CS1 maint: overridden setting (link)